Pulmatrix Inc. (PULM)
NasdaqCM: PULM
· Real-Time Price · USD
1.60
+0.00 (0.00%)
At close: Aug 11, 2026, 3:49 PM
Pulmatrix Inc. (PULM) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 1.47 |
| Market Cap | 5.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.53M |
| Beta | 1.92 |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.36 |
| P/B (ttm) | 2.21 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.6 |
| Volume | 609 |
| Avg. Volume (20D) | 48,920 |
| Open | 1.59 |
| Previous Close | 1.60 |
| Day's Range | 1.60 - 1.60 |
| 52-Week Range | 1.16 - 5.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PULM
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectru...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 2014
Employees 2
Stock Exchange NasdaqCM
Ticker Symbol PULM
Website https://www.pulmatrix.com
Financial Performance
In 2025, Pulmatrix's revenue was 0, a decrease of -100% compared to the previous year's 7.81M. Earnings were -5.16M, a decrease of -46%.
Financial StatementsEarnings Surprise
Pulmatrix has released their quarterly earnings on Nov 9, 2023:
